Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine; Drug: carboplatin; Drug: epirubicin hydrochloride; Genetic: microarray analysis; Genetic: polymorphism analysis; Other: pharmacological study

Sponsors: University of Nebraska; National Cancer Institute (NCI)

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 4, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments